Evidence map›Paper›PMID 39017828›Full record

ReviewCurrent neurology and neuroscience reports2024

CGRP Modulating Therapies: An Update.

Kate Bedrin, Tulsi Shah, Shivani Vaidya, Jessica Ailani

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current neurology and neuroscience reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Kate BedrinVirginia Mason Franciscan Health, Seattle, USA. Kate.Bedrin@commonspirit.org.
Tulsi ShahMedstar Georgetown University Hospital, Washington, USA.
Shivani VaidyaMedstar Georgetown University Hospital, Washington, USA.
Jessica AilaniMedstar Georgetown University Hospital, Washington, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCalcitonin-gene related peptide (CGRP) is a vasoactive neuropeptide involved in the pathophysiology ofmigraine. CGRP has been targeted for both preventive and acute treatment of migraine.

objectiveProvide a summary of the most clinically relevant literature surrounding CGRP modulating therapies.

methodsThis update on CGRP modulating therapies includes articles selected as most clinically relevant by theauthors.

conclusionCGRP modulating therapies are an exciting new addition to migraine treatment given their safety andtolerability. Additionally, compared to traditional migraine preventive medication these treatments are migrainespecific.Further real-world and clinical data is ongoing to better understand these treatments that continue to gainfavor in the management of migraine.

Indexed as

Calcitonin Gene-Related PeptideMigraine DisordersCalcitonin Gene-Related Peptide Receptor AntagonistsHumansCalcitonin Gene-Related PeptideCalcitonin Gene-Related Peptide Receptor AntagonistsCalcitonin gene-related peptideCalcitonin gene-related peptide monoclonal antibodyCalcitonin gene-related peptide receptor antagonistMigraine treatmentMigraine without aura

Identifiers

PMID39017828

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.